MLLT6
Summary:
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| MLLT6, PHD finger containing | MIM:600328 | Ensembl:ENSG00000275023 | HGNC:HGNC:7138 | PA30854 | 17q12 |
GO terms in MLLT6
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IPI | GO:0005515 | protein binding |
| MF | IDA | GO:0031491 | nucleosome binding |
| MF | IPI | GO:0042393 | histone binding |
| MF | IEA | GO:0046872 | metal ion binding |
| BP | TAS | GO:0006355 | regulation of transcription, DNA-templated |
| CC | IEA | GO:0005634 | nucleus |
Gene expression in normal tissue: MLLT6
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in MLLT6
| Database | Pathway ID | Pathway Des. |
|---|
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD512 | nutlin 3 | 3 |
| iGMDRD532 | Olaparib | 3 |
| iGMDRD345 | Compound 10b [PMID: 11504634] | 1 |
| iGMDRD639 | YK 4-279 | 3 |
| iGMDRD193 | Fqi1 | 3 |
| iGMDRD446 | LY 2183240 | 3 |
| iGMDRD901 | ELCPK | 3 |
| iGMDRD513 | BML-259 | 3 |
| iGMDRD137 | Indisulam | 3 |
| iGMDRD318 | PAC-1 | 3 |
| iGMDRD434 | BMS-536924 | 5 |
| iGMDRD506 | Fedratinib | 6 |
| iGMDRD577 | BIX01294 | 2 |
| iGMDRD562 | Navitoclax | 6 |
| iGMDRD100 | Zebularine | 4 |
| iGMDRD188 | Piperlongumine | 3 |
| iGMDRD367 | Ro 28-1675 | 3 |
| iGMDRD730 | Kahalalide F | 3 |
| iGMDRD74 | Idarubicin | 3 |
| iGMDRD23 | Gossypol | 3 |
| iGMDRD300 | Tozasertib | 3 |
| iGMDRD886 | Compound 1541A | 3 |
| iGMDRD552 | AZD-1775 | 1 |
| iGMDRD60 | Quinoclamine | 1 |
| iGMDRD64 | Parbendazole | 3 |
| iGMDRD246 | NPC26 | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in MLLT6
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.